

David I Marks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11776244/publications.pdf>

Version: 2024-02-01

95
papers

10,153
citations

57758

44
h-index

51608

86
g-index

95
all docs

95
docs citations

95
times ranked

8274
citing authors

#	ARTICLE	IF	CITATIONS
1	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
2	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. <i>Leukemia</i> , 2022, 36, 625-636.	7.2	25
3	The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL). <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	1.3	0
4	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. <i>Lancet Haematology</i> , 2022, 9, e276-e288.	4.6	12
5	Repeat infusion of autologous bone marrow cells in progressive multiple sclerosis – A phase I extension study (SIAMMS II). <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103782.	2.0	0
6	Molecular classification improves risk assessment in adult <i>t</i> (9;22) BCR-ABL1 negative B-ALL. <i>Blood</i> , 2021, 138, 948-958.	1.4	59
7	A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT). <i>Journal of Clinical Oncology</i> , 2021, 39, 7017-7017.	1.6	1
8	Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation. <i>Blood Advances</i> , 2021, , .	5.2	0
9	Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. <i>Leukemia and Lymphoma</i> , 2020, 61, 491-493.	1.3	2
10	Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients. <i>EJHaem</i> , 2020, 1, 208-218.	1.0	3
11	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	1.6	36
12	At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. <i>British Journal of Haematology</i> , 2020, 191, 37-43.	2.5	9
13	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10
14	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
15	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
16	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1247-1256.	2.0	139
17	Recent Advances in the Management of Acute Lymphoblastic Leukaemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 23.	3.0	16
18	Intention to Treat Analysis of Real-World Outcomes Following Tisagenlecleucel Therapy for Pediatric and Young Adult ALL through a National Access Programme. <i>Blood</i> , 2020, 136, 18-19.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment. <i>Cancer Medicine</i> , 2019, 8, 5959-5968.	2.8	8
20	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
21	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
22	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
23	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
24	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	2.4	106
25	Acute Lymphoblastic Leukemia in Adults. , 2019, , 531-538.		4
26	Reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 2151-2160.	4.1	44
27	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
28	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
29	Extensive cardiac infiltration in acute T-cell lymphoblastic leukemia: occult extra-medullary relapse and remission after salvage chemotherapy. <i>European Heart Journal</i> , 2017, 38, ehw393.	2.2	5
30	Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 143-152.	2.3	12
31	Management of adults with T-cell lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 1134-1142.	1.4	119
32	Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 493-502.	4.4	15
33	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , 2017, 4, e387-e398.	4.6	158
34	International variations in the use of haematopoietic cell transplantation for haematological malignancies: the effects of national transplant indications tables and differing access to therapies. <i>British Journal of Haematology</i> , 2017, 179, 5-7.	2.5	0
35	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	512
36	Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. <i>Mycoses</i> , 2017, 60, 79-88.	4.0	7

#	ARTICLE	IF	CITATIONS
37	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. American Journal of Hematology, 2017, 92, 42-49.	4.1	46
38	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1636-1645.	2.0	71
39	Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial. Trials, 2015, 16, 463.	1.6	37
40	Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II). BMJ Open, 2015, 5, e009090.	1.9	14
41	The Challenges of Managing Older Patients with Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e343-e351.	3.8	9
42	Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infectious Diseases, 2015, 15, 128.	2.9	46
43	Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1863-1869.	2.0	342
44	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 151-158.	2.0	49
45	Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America, 2014, 28, 995-1009.	2.2	14
46	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1777-1784.	2.0	50
47	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
48	Allotransplantation for Patients Age ≥ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
49	Avascular Necrosis of Bone after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. Biology of Blood and Marrow Transplantation, 2014, 20, 587-592.	2.0	33
50	UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood, 2014, 123, 843-850.	1.4	321
51	Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica, 2014, 99, 322-328.	3.5	79
52	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica, 2013, 98, 945-952.	3.5	54
53	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. Biology of Blood and Marrow Transplantation, 2012, 18, 1255-1264.	2.0	27
54	Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. Current Hematologic Malignancy Reports, 2012, 7, 160-169.	2.3	10

#	ARTICLE	IF	CITATIONS
55	Outcomes in older adults with acute lymphoblastic leukaemia (<scp>ALL</scp>): results from the international <scp>MRC UKALL XII</scp>/<scp>ECOG</scp>2993 trial. <i>British Journal of Haematology</i> , 2012, 157, 463-471.	2.5	161
56	Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia in Adults. , 2011, , 297-304.		0
57	One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood and Marrow Transplant Research Results in the Era of Molecular HLA Typing. <i>Biology of Blood and Marrow Transplantation</i> . 2011, 17, 640-648.	2.0	55
58	Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1869-1873.	2.0	31
59	Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Blood</i> , 2011, 117, 6963-6970.	1.4	322
60	Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2011, 155, 318-327.	2.5	205
61	Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> . 2011, 118, 494-494.	1.4	0
62	The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. <i>Blood</i> , 2010, 116, 366-374.	1.4	178
63	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. <i>Blood</i> , 2010, 116, 1839-1848.	1.4	168
64	Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure. <i>Journal of Clinical Oncology</i> , 2010, 28, 3730-3738.	1.6	386
65	Treating the "Older" Adult With Acute Lymphoblastic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 13-20.	2.5	25
66	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 35-45.	2.0	88
67	Outcome of Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 358-367.	2.0	245
68	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. <i>Lancet Oncology</i> , The, 2010, 11, 653-660.	10.7	532
69	Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia in Adults. , 2010, , 193-202.		0
70	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. <i>Haematologica</i> , 2009, 94, 1399-1406.	3.5	34
71	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). <i>Blood</i> , 2009, 114, 5136-5145.	1.4	346
72	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 113, 3110-3118.	1.4	147

#	ARTICLE	IF	CITATIONS
73	Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome ⁺ positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. <i>Blood</i> , 2009, 113, 4489-4496.	1.4	257
74	Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2009, 114, 872-872.	1.4	4
75	Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 236-245.	2.0	157
76	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 111, 1827-1833.	1.4	702
77	Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. <i>Blood</i> , 2008, 112, 426-434.	1.4	80
78	Response: Unrelated donor transplantation for adults with Ph ⁺ ALL in first complete remission. <i>Blood</i> , 2008, 112, 448-449.	1.4	1
79	Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment: Results from the CIBMTR. <i>Blood</i> , 2008, 112, 794-794.	1.4	1
80	Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. <i>Blood</i> , 2007, 109, 944-950.	1.4	716
81	Does Imatinib Change the Outcome in Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study. <i>Blood</i> , 2007, 110, 8-8.	1.4	22
82	Preparations for unrelated donor transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 403-408.	1.3	1
83	A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 438-453.	2.0	182
84	Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. <i>Blood</i> , 2006, 107, 1724-1730.	1.4	169
85	Haploidentical stem cell transplantation for children with acute leukaemia. <i>British Journal of Haematology</i> , 2006, 134, 196-201.	2.5	92
86	A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation. <i>Blood</i> , 2006, 108, 3002-3002.	1.4	0
87	Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia. <i>New England Journal of Medicine</i> , 2004, 351, 2265-2275.	27.0	1,019
88	Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know. <i>Blood</i> , 2004, 104, 295-296.	1.4	4
89	The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. <i>British Journal of Haematology</i> , 2003, 123, 886-895.	2.5	21
90	Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. <i>Blood</i> , 2003, 102, 3521-3529.	1.4	339

#	ARTICLE	IF	CITATIONS
91	The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Blood</i> , 2002, 100, 3108-3114.	1.4	209
92	The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. <i>British Journal of Haematology</i> , 2001, 113, 58-64.	2.5	131
93	Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction. <i>British Journal of Haematology</i> , 2000, 108, 132-139.	2.5	122
94	The outcome of children requiring admission to an intensive care unit following bone marrow transplantation. <i>British Journal of Haematology</i> , 1998, 102, 666-670.	2.5	54
95	Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission. <i>British Journal of Haematology</i> , 1997, 99, 36-40.	2.5	20